Orion Corporation upgrades the full-year outlook estimate for 2012 provided on 3 July 2012. The company estimates that the full-year operating profit will be higher than estimated in the previous outlook.
New full-year outlook estimate for 2012, provided on 9 October 2012
Net sales will be slightly higher than in 2011.
Operating profit will be at similar level to 2011.
The Group's capital expenditure will be about EUR 50 million excluding substantial corporate or product acquisitions.
Previous full-year outlook estimate for 2012, provided on 3 July 2012
Net sales will be slightly higher than in 2011.
Operating profit will be slightly higher than in 2010.
The Group's capital expenditure will be about EUR 50 million excluding substantial corporate or product acquisitions.
Orion will publish the Interim Report January-September 2012 on Tuesday, 23 October 2012.
Orion Corporation
Timo Lappalainen Olli Huotari
President and CEO SVP, Corporate Functions
Contact person:
Jari Karlson, CFO, tel. +358 10 426 2883
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
www.orion.fi
twitter.com/OrionCorpIR
Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs.
Orion's net sales in 2011 amounted to EUR 918 million and the company had about 3,400 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.